Results 101 to 110 of about 7,695 (151)

A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose. [PDF]

NPJ Vaccines
Rostad CA, Yildirim I, Kao C, Yi J, Kamidani S, Peters E, Stephens K, Gibson T, Hsiao HM, Singh K, Spearman P, McCracken C, Agbakoba V, Tomashek KM, Goll JB, Gelber CE, Johnson RA, Lee S, Maner-Smith K, Bosinger S, Ortlund EA, Chen X, Anderson LJ, Wrammert J, Suthar M, Rouphael N, Anderson EJ.   +26 more
europepmc   +1 more source

Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development. [PDF]

Ann Med Surg (Lond)
Paison F, Ubuzima P, Nshimiyimana E, Habumugisha J, Atukunda S, Ayebare F, Munyurangabo G, Amikoro B, Su B.   +8 more
europepmc   +1 more source

Jamaican fruit bats' competence for Ebola but not Marburg virus is driven by intrinsic differences. [PDF]

Nat Commun
van Tol S, Port JR, Fischer RJ, Gallogly S, Bushmaker T, Griffin A, Schulz JE, Carmody A, Myers L, Crowley DE, Falvo CA, Riopelle JC, Wickenhagen A, Clancy C, Lovaglio J, Shaia C, Saturday G, Prado-Smith J, He Y, Lack J, Martens C, Anzick SL, Kendall LV, Schountz T, Plowright RK, Marzi A, Munster VJ.   +26 more
europepmc   +1 more source

Lack of Lloviu Virus Disease Development in Ferret Model. [PDF]

Emerg Infect Dis
Fletcher P, O'Donnell KL, Rhoderick JF, Henderson CW, Okumura A, Bushmaker T, Takada A, Clancy CS, Kemenesi G, Marzi A.   +9 more
europepmc   +1 more source

Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection. [PDF]

PLoS Pathog
Bu F, Ye G, Morsheimer K, Mendoza A, Turner-Hubbard H, Herbst M, Spiller B, Wadzinski BE, Eaton B, Anantpadma M, Yang G, Liu B, Davey R, Li F.   +13 more
europepmc   +1 more source

Lipid Selectivity of Membrane Action of the Fragments of Fusion Peptides of Marburg and Ebola Viruses. [PDF]

Int J Mol Sci
Shekunov EV, Efimova SS, Kever LV, Ishmanov TF, Ostroumova OS.   +4 more
europepmc   +1 more source

Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates. [PDF]

Nat Med
Cross RW, Woolsey C, Prasad AN, Borisevich V, Agans KN, Deer DJ, Harrison MB, Dobias NS, Fenton KA, Cihlar T, Nguyen AQ, Babusis D, Bannister R, Vermillion MS, Chu VC, Geisbert TW.   +15 more
europepmc   +1 more source

Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies. [PDF]

PLoS Pathog
Wirchnianski AS, Nyakatura EK, Herbert AS, Kuehne AI, Abbasi SA, Florez C, Storm N, McKay LGA, Dailey L, Kuang E, Abelson DM, Wec AZ, Chakraborti S, Holtsberg FW, Shulenin S, Bornholdt ZA, Aman MJ, Honko AN, Griffiths A, Dye JM, Chandran K, Lai JR.   +21 more
europepmc   +1 more source

Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus. [PDF]

Nat Commun
Prasad AN, Woolsey C, Borisevich V, Agans KN, Deer DJ, Geisbert JB, Harrison MB, Dobias NS, Fenton KA, Cross RW, Geisbert TW.   +10 more
europepmc   +1 more source

Phylogenetic analysis of the promoter element 2 of paramyxo- and filoviruses. [PDF]

Microbiol Spectr
Ashida S, Kojima S, Okura T, Kato F, Furuyama W, Urata S, Matsumoto Y.   +6 more
europepmc   +1 more source